الفهرس 
cover englshOnly 14 pages are availabe for public view
 |  | from | 189 |  |  |
| | | from | 189 | | |
Abstract
CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL) Accounts For Approximately 40% Of New Cases Of Lymphoma. DLBCL Is A Heterogeneous Disease That Includes At Least Two Prognostically Important Subtypes (I.E. Germinal Center B-Cell Like [GCB] And Non-Germinal Center B-Cell Like [Non-GCB]). These Subtypes Initially Were characterized By Gene Expression Profiling And Subsequently Were Confirmed By Immunostaining.